[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Wal Mart Stores, Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":110},{"warningLetters":4,"total":109},[5,32,53,72,91],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":31,"medical_device_id":20,"response_letter_date":20},21695,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-01T04:00:00Z\">10\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwalmart-inc-736557-10012026\">Walmart, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs\u003Cbr \u002F>\r\n","","Unapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>John Furner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Walmart, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>702 SW 8th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bentonville\u003C\u002Fspan>, \u003Cspan>AR\u003C\u002Fspan> \u003Cspan>72716-6299\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:HWSCSAFETY@wal-mart.com\"> HWSCSAFETY@wal-mart.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 1, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference Number: 736557\u003C\u002Fp>\u003Cp>To John Furner:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of drug products that were purchased on your website, www.walmart.com, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>As discussed below, the “HClear for him,” “Herstat GST,” and “Terragen HG Formula” products available for purchase on your website are unapproved new drugs. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and\u002For their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during review of the product labeling of products purchased on your website www.walmart.com in July 2026. FDA purchased, “HClear for him,” “Herstat GST,” and “Terragen HG Formula” through your website, and these products were introduced or delivered for introduction into interstate commerce by Walmart via your Walmart Fulfillment Services.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Based on our review, “HClear for him,” “Herstat GST,” and “Terragen HG Formula” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on a review of your website, “HClear for him,” “Herstat GST,”\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and “Terragen HG Formula” are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims observed on the product labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>HClear for him\u003C\u002Fu>\u003C\u002Fp>\u003Cul>\u003Cli>“GENITAL HERPES SYMPTOMS”\u003C\u002Fli>\u003Cli>“&gt;90 of USERS REPORTED LESS SEVERE OUTBREAKS”\u003C\u002Fli>\u003Cli>“FAST-ACTING OUTBREAK SYMPTOM RELIEF ITCHING, TINGLING, PAIN &amp; BURNING”\u003C\u002Fli>\u003Cli>“[I]ntended to relieve symptoms associated with diagnosed genital herpes, including itching, burning and\u002For pain.”\u003C\u002Fli>\u003Cli>“[B]est used at first sign of outbreak. Early use ensures the best results.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Herstat GST\u003C\u002Fu>\u003C\u002Fp>\u003Cul>\u003Cli>“Genital Sore Treatment”\u003C\u002Fli>\u003Cli>“Soothes and calms genital sores”\u003C\u002Fli>\u003Cli>“[R]elieves pain and itching associated with genital sores.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Terragen HG Formula\u003C\u002Fu>\u003C\u002Fp>\u003Cul>\u003Cli>“Uses . . . relief of swelling and pain associated with genital sores.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>“HClear for him,” “Herstat GST,” and “Terragen HG Formula” are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>We recognize that the “Terragen HG Formula” product available for purchase on your website is labeled as a homeopathic drug with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “760337” in the subject line of the email.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Walmart distributed each of the products directly to individual U.S. consumers on behalf of third parties. Each of the products discussed below were “fulfilled” by Walmart; your website states, “Walmart Fulfillment Services (WFS) allows Marketplace sellers to leverage Walmart’s end-to-end logistics services, from imports to storage to 2-day fulfillment[] and beyond. When a customer places an order on Walmart.com, we’ll pick, pack and ship the item to the customer on the seller’s behalf. WFS also handles all customer support and returns for these orders.” (See https:\u002F\u002Fmarketplacelearn.walmart.com\u002Fguides\u002FWalmart%20Fulfillment%20Services%20(WFS)\u002FWFS%20basics\u002Fwalmart-fulfillment-services-wfs-overview).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The permitted indications under OTC Monograph M017: External Analgesic Drug Products for OTC Human Use (M017) are for the treatment of pain, itching, and minor skin irritation generally and for the prevention of premature ejaculation. The “Herstat GST” product available for purchase on your website is intended to provide relief from genital sores and their associated symptoms, which goes beyond the permissible indications under M017. “Herstat GST” therefore does not conform to M017 or any other final OTC administrative order. Accordingly, there is no basis under section 505G of the FD&amp;C Act under which “Herstat GST” could be legally marketed without an approved application. (see https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfdadocs\u002Fomuf\u002Fmonographs\u002FOTC%20MonographM017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> We recognize that the “HClear for him” product available for purchase on your website is also labeled as being “homeopathic.” FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for certain categories of homeopathic drug products that potentially pose a higher risk to public health. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” “Hclear for him” does not meet the definition of a “homeopathic drug product” because it includes “lemongrass 2X HPUS,” which is not listed in the HPUS as an active ingredient. Therefore, this product falls outside the scope of products addressed in this guidance.\u003C\u002Fp>\u003Cp>Notwithstanding, even if the above listed product is considered a “homeopathic drug product\" under this guidance, this product would fall under the guidance’s category of homeopathic drug products marketed without the required FDA approval that FDA views as potentially posing higher risks to public health and thus intends to prioritize for enforcement and regulatory actions.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nJohn Furner\n\nRecipient Title\n\nPresident and CEO\n\nWalmart, Inc.\n\n702 SW 8th Street\n\nBentonville, AR 72716-6299\n\nUnited States\n\nHWSCSAFETY@wal-mart.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 1, 2026\nWARNING LETTER\nReference Number: 736557\nTo John Furner:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of drug products that were purchased on your website, www.walmart.com, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nAs discussed below, the “HClear for him,” “Herstat GST,” and “Terragen HG Formula” products available for purchase on your website are unapproved new drugs. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and\u002For their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.\nFDA Review\nViolations were identified and documented during review of the product labeling of products purchased on your website www.walmart.com in July 2026. FDA purchased, “HClear for him,” “Herstat GST,” and “Terragen HG Formula” through your website, and these products were introduced or delivered for introduction into interstate commerce by Walmart via your Walmart Fulfillment Services.1 Based on our review, “HClear for him,” “Herstat GST,” and “Terragen HG Formula” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nThis review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nBased on a review of your website, “HClear for him,” “Herstat GST,”2 and “Terragen HG Formula” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims observed on the product labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nHClear for him\n“GENITAL HERPES SYMPTOMS”\n“>90 of USERS REPORTED LESS SEVERE OUTBREAKS”\n“FAST-ACTING OUTBREAK SYMPTOM RELIEF ITCHING, TINGLING, PAIN & BURNING”\n“[I]ntended to relieve symptoms associated with diagnosed genital herpes, including itching, burning and\u002For pain.”\n“[B]est used at first sign of outbreak. Early use ensures the best results.”\nHerstat GST\n“Genital Sore Treatment”\n“Soothes and calms genital sores”\n“[R]elieves pain and itching associated with genital sores.”\nTerragen HG Formula\n“Uses . . . relief of swelling and pain associated with genital sores.”\n“HClear for him,” “Herstat GST,” and “Terragen HG Formula” are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nWe recognize that the “Terragen HG Formula” product available for purchase on your website is labeled as a homeopathic drug with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.3\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “760337” in the subject line of the email.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n______________________\n1 Walmart distributed each of the products directly to individual U.S. consumers on behalf of third parties. Each of the products discussed below were “fulfilled” by Walmart; your website states, “Walmart Fulfillment Services (WFS) allows Marketplace sellers to leverage Walmart’s end-to-end logistics services, from imports to storage to 2-day fulfillment[] and beyond. When a customer places an order on Walmart.com, we’ll pick, pack and ship the item to the customer on the seller’s behalf. WFS also handles all customer support and returns for these orders.” (See https:\u002F\u002Fmarketplacelearn.walmart.com\u002Fguides\u002FWalmart%20Fulfillment%20Services%20(WFS)\u002FWFS%20basics\u002Fwalmart-fulfillment-services-wfs-overview).\n2 The permitted indications under OTC Monograph M017: External Analgesic Drug Products for OTC Human Use (M017) are for the treatment of pain, itching, and minor skin irritation generally and for the prevention of premature ejaculation. The “Herstat GST” product available for purchase on your website is intended to provide relief from genital sores and their associated symptoms, which goes beyond the permissible indications under M017. “Herstat GST” therefore does not conform to M017 or any other final OTC administrative order. Accordingly, there is no basis under section 505G of the FD&C Act under which “Herstat GST” could be legally marketed without an approved application. (see https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfdadocs\u002Fomuf\u002Fmonographs\u002FOTC%20MonographM017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf).\n3 We recognize that the “HClear for him” product available for purchase on your website is also labeled as being “homeopathic.” FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for certain categories of homeopathic drug products that potentially pose a higher risk to public health. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” “Hclear for him” does not meet the definition of a “homeopathic drug product” because it includes “lemongrass 2X HPUS,” which is not listed in the HPUS as an active ingredient. Therefore, this product falls outside the scope of products addressed in this guidance.\nNotwithstanding, even if the above listed product is considered a “homeopathic drug product\" under this guidance, this product would fall under the guidance’s category of homeopathic drug products marketed without the required FDA approval that FDA views as potentially posing higher risks to public health and thus intends to prioritize for enforcement and regulatory actions.","Walmart, Inc.","walmart-inc-736557-10012026","2026-10-14T12:31:16.41489+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwalmart-inc-736557-10012026","2026-11-17T01:02:03.701861+00:00","Warning Letter","Issued","2026-10-06","736557","Drugs Over-the-Counter Drugs","John Furner","2026-10-14T12:34:09.03+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-10-01",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":17,"letter_id":42,"created_at":43,"fei_number":20,"letter_url":44,"updated_at":45,"action_type":23,"case_status":24,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":20,"issuing_office":38,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":20,"reference_number":20,"action_taken_date":52,"medical_device_id":20,"response_letter_date":20},424,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2025-12-15T05:00:00Z\">12\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-12T05:00:00Z\">12\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwalmart-inc-720400-12122025\">Walmart, Inc. \u003C\u002Fa>","Human Foods Program","Infant Botulism Outbreak","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Doug McMillon\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Walmart, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>702 SW 8th Street, Ms 275\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bentonville\u003C\u002Fspan>, \u003Cspan>AR\u003C\u002Fspan> \u003Cspan>72716-6299\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 12, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #720400\u003C\u002Fp>\u003Cp>Dear Mr. McMillon:\u003C\u002Fp>\u003Cp>Beginning in November 2025, the U.S. Food and Drug Administration (FDA), in collaboration with the Centers for Disease Control and Prevention (CDC), the California Department of Public Health (CDPH), Infant Botulism Treatment and Prevention Program (IBTPP), and state and local partners, has been investigating a multistate outbreak of infant botulism linked to ByHeart Whole Nutrition Infant Formula. As of December 10, 2025, CDC reported that 51 infants from 19 states have suspected or confirmed infant botulism.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Infants range from 16 to 264 days of age. Based on epidemiological evidence, CDC has determined that ByHeart Whole Nutrition Infant Formula was the source of this multistate infant botulism outbreak.\u003C\u002Fp>\u003Cp>The presence of \u003Cem>Clostridium botulinum\u003C\u002Fem> in ByHeart Whole Nutrition Infant Formula, as evidenced by the recent foodborne outbreak, causes these products to be adulterated within the meaning of section 402(a)(1) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 342(a)(1)] in that they bear or contain an added poisonous or deleterious substance which may render them injurious to health.\u003C\u002Fp>\u003Cp>On November 8, 2025, ByHeart Inc. (ByHeart) initiated a voluntary recall of \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of its ByHeart Whole Nutrition Infant Formula. Walmart was notified in writing on November 8, 2025, of this voluntary recall. On November 11, 2025, ByHeart expanded the recall to all ByHeart Whole Nutrition Infant Formula, including all unexpired lots of formula cans and single-serve “anywhere pack” sticks. As a consignee of the recalled products, Walmart was notified in writing on November 11, 2025, that the scope of the voluntary recall had expanded to include all ByHeart infant formula products. Despite these recall notifications, subsequent visits by regulators confirmed that recalled ByHeart Whole Nutrition Infant Formula remained available for purchase on shelves in at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> Walmart stores across 21 states well after the recall was initiated and subsequently expanded. The receipt in interstate commerce of adulterated food, and the delivery or proffered delivery thereof for pay or otherwise, is a violation of section 301(c) of the FD&amp;C Act [21 U.S.C. § 331(c)]. You can find the FD&amp;C Act and its implementing regulations through links on FDA’s home page at https:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Infant Botulism Investigation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Infants can develop infant botulism when a baby swallows \u003Cem>Clostridium botulinum\u003C\u002Fem> spores that grow in the immature gut and produce toxin. Most infants with infant botulism will initially develop constipation, poor feeding, loss of head control, and difficulty swallowing, which can progress to difficulty breathing and respiratory arrest. Symptoms of infant botulism, which is diagnosed clinically, can take as long as several weeks to develop following formula ingestion.\u003C\u002Fp>\u003Cp>State and local public health officials are interviewing caregivers about the foods their infants consumed during the month prior to illness onset. All 51 previously reported infant botulism cases were infants who had been fed ByHeart Whole Nutrition Infant Formula before becoming sick.\u003C\u002Fp>\u003Cp>As part of its onsite inspections, FDA collected and is currently analyzing unopened product samples. This analysis is ongoing, and results will be shared as they become available. Additional testing by FDA, CDC, and state partners is also underway, with results expected in the coming weeks. Because detection of \u003Cem>Clostridium botulinum\u003C\u002Fem> in infant formula is scientifically complex, a negative test result does not rule out the presence of the bacteria in the product.\u003C\u002Fp>\u003Cp>\u003Cstrong>Receipt and Offer of Adulterated Foods\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As noted above, FDA investigators and state and local partners reported that recalled ByHeart formula continued to be found on Walmart store shelves in multiple locations across multiple states. FDA and state partners have worked with retailers to ensure an effective recall and immediate removal of these products from all store shelves nationwide. All ByHeart infant formula products have been recalled, including all formula cans and single-serve “anywhere pack” sticks, and these products must not be available for sale in stores or online. The receipt in interstate commerce of adulterated food, and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&amp;C Act [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As a participant in the supply chain, your firm should take prompt and effective action when notified of a product recall. Once your firm has been made aware of a recall or potential safety issue, you should take action to immediately remove the affected product from distribution and sale, cease all further shipment or use, and implement all necessary measures to prevent further exposure to consumers or downstream distribution.\u003C\u002Fp>\u003Cp>However, based on FDA’s review of information from state and local partners, the Agency determined that recalled ByHeart Whole Nutrition Infant Formula remained on shelves at \u003Cstrong>(b)(4)\u003C\u002Fstrong> Walmart store locations across 21 states from November 12 to November 26, 2025. This represents a period of \u003Cstrong>(b)(4)\u003C\u002Fstrong> days after Walmart was notified of the recall expansion. State and local partners reported several explanations offered by Walmart store associates for the continued presence of the recalled product, including lack of awareness of the recall notice, confusion regarding which specific lots were affected, failure to remove all impacted product, and stocking products that arrived after the recall notification.\u003C\u002Fp>\u003Cp>On November 18, 2025, FDA held a call with you to discuss the ineffectiveness of the recall within your Walmart stores. During this discussion, FDA requested information regarding actions you were prepared to implement to ensure recalled product was no longer available for purchase at Walmart stores nationwide. Despite follow-up emails from the FDA on November 20, 21, and 24, 2025, and December 1, 3, and 8, 2025, you have not provided FDA with any information demonstrating that corrective actions to effectuate this recall have been implemented throughout your organization to prevent adulterated food from being received in interstate commerce and subsequently offered for sale.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with the food you receive and offer for sale at your establishments. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe you are not in violation of the FD&amp;C Act, include your reasoning and any supportive information for our consideration.\u003C\u002Fp>\u003Cp>Please send your reply via email to: HFP-OCE-EmergingIssues@fda.hhs.gov, copying Katherine Arnold, Compliance Officer, at Katherine.Arnold@fda.hhs.gov. If you have any questions regarding any issues in this letter, please contact Katherine Arnold, Compliance Officer, via email at Katherine.Arnold@fda.hhs.gov. Please include CMS reference #720400 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Ann M. Oxenham, JD\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>__________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As of December 10, 2025, CDC broadened the definition for the outbreak investigation to include any infant with botulism who was exposed to ByHeart infant formula at any time since the product’s release in March 2022.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nDoug McMillon\n\nRecipient Title\n\nCEO\n\nWalmart, Inc.\n\n702 SW 8th Street, Ms 275\n\nBentonville, AR 72716-6299\n\nUnited States\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nDecember 12, 2025\nWARNING LETTER\nCMS #720400\nDear Mr. McMillon:\nBeginning in November 2025, the U.S. Food and Drug Administration (FDA), in collaboration with the Centers for Disease Control and Prevention (CDC), the California Department of Public Health (CDPH), Infant Botulism Treatment and Prevention Program (IBTPP), and state and local partners, has been investigating a multistate outbreak of infant botulism linked to ByHeart Whole Nutrition Infant Formula. As of December 10, 2025, CDC reported that 51 infants from 19 states have suspected or confirmed infant botulism.1 Infants range from 16 to 264 days of age. Based on epidemiological evidence, CDC has determined that ByHeart Whole Nutrition Infant Formula was the source of this multistate infant botulism outbreak.\nThe presence of Clostridium botulinum in ByHeart Whole Nutrition Infant Formula, as evidenced by the recent foodborne outbreak, causes these products to be adulterated within the meaning of section 402(a)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 342(a)(1)] in that they bear or contain an added poisonous or deleterious substance which may render them injurious to health.\nOn November 8, 2025, ByHeart Inc. (ByHeart) initiated a voluntary recall of (b)(4) lots of its ByHeart Whole Nutrition Infant Formula. Walmart was notified in writing on November 8, 2025, of this voluntary recall. On November 11, 2025, ByHeart expanded the recall to all ByHeart Whole Nutrition Infant Formula, including all unexpired lots of formula cans and single-serve “anywhere pack” sticks. As a consignee of the recalled products, Walmart was notified in writing on November 11, 2025, that the scope of the voluntary recall had expanded to include all ByHeart infant formula products. Despite these recall notifications, subsequent visits by regulators confirmed that recalled ByHeart Whole Nutrition Infant Formula remained available for purchase on shelves in at least (b)(4) Walmart stores across 21 states well after the recall was initiated and subsequently expanded. The receipt in interstate commerce of adulterated food, and the delivery or proffered delivery thereof for pay or otherwise, is a violation of section 301(c) of the FD&C Act [21 U.S.C. § 331(c)]. You can find the FD&C Act and its implementing regulations through links on FDA’s home page at https:\u002F\u002Fwww.fda.gov.\nInfant Botulism Investigation\nInfants can develop infant botulism when a baby swallows Clostridium botulinum spores that grow in the immature gut and produce toxin. Most infants with infant botulism will initially develop constipation, poor feeding, loss of head control, and difficulty swallowing, which can progress to difficulty breathing and respiratory arrest. Symptoms of infant botulism, which is diagnosed clinically, can take as long as several weeks to develop following formula ingestion.\nState and local public health officials are interviewing caregivers about the foods their infants consumed during the month prior to illness onset. All 51 previously reported infant botulism cases were infants who had been fed ByHeart Whole Nutrition Infant Formula before becoming sick.\nAs part of its onsite inspections, FDA collected and is currently analyzing unopened product samples. This analysis is ongoing, and results will be shared as they become available. Additional testing by FDA, CDC, and state partners is also underway, with results expected in the coming weeks. Because detection of Clostridium botulinum in infant formula is scientifically complex, a negative test result does not rule out the presence of the bacteria in the product.\nReceipt and Offer of Adulterated Foods\nAs noted above, FDA investigators and state and local partners reported that recalled ByHeart formula continued to be found on Walmart store shelves in multiple locations across multiple states. FDA and state partners have worked with retailers to ensure an effective recall and immediate removal of these products from all store shelves nationwide. All ByHeart infant formula products have been recalled, including all formula cans and single-serve “anywhere pack” sticks, and these products must not be available for sale in stores or online. The receipt in interstate commerce of adulterated food, and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&C Act [21 U.S.C. § 331(c)].\nAs a participant in the supply chain, your firm should take prompt and effective action when notified of a product recall. Once your firm has been made aware of a recall or potential safety issue, you should take action to immediately remove the affected product from distribution and sale, cease all further shipment or use, and implement all necessary measures to prevent further exposure to consumers or downstream distribution.\nHowever, based on FDA’s review of information from state and local partners, the Agency determined that recalled ByHeart Whole Nutrition Infant Formula remained on shelves at (b)(4) Walmart store locations across 21 states from November 12 to November 26, 2025. This represents a period of (b)(4) days after Walmart was notified of the recall expansion. State and local partners reported several explanations offered by Walmart store associates for the continued presence of the recalled product, including lack of awareness of the recall notice, confusion regarding which specific lots were affected, failure to remove all impacted product, and stocking products that arrived after the recall notification.\nOn November 18, 2025, FDA held a call with you to discuss the ineffectiveness of the recall within your Walmart stores. During this discussion, FDA requested information regarding actions you were prepared to implement to ensure recalled product was no longer available for purchase at Walmart stores nationwide. Despite follow-up emails from the FDA on November 20, 21, and 24, 2025, and December 1, 3, and 8, 2025, you have not provided FDA with any information demonstrating that corrective actions to effectuate this recall have been implemented throughout your organization to prevent adulterated food from being received in interstate commerce and subsequently offered for sale.\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with the food you receive and offer for sale at your establishments. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe you are not in violation of the FD&C Act, include your reasoning and any supportive information for our consideration.\nPlease send your reply via email to: HFP-OCE-EmergingIssues@fda.hhs.gov, copying Katherine Arnold, Compliance Officer, at Katherine.Arnold@fda.hhs.gov. If you have any questions regarding any issues in this letter, please contact Katherine Arnold, Compliance Officer, via email at Katherine.Arnold@fda.hhs.gov. Please include CMS reference #720400 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nAnn M. Oxenham, JD\nDirector\nOffice of Compliance and Enforcement\nHuman Foods Program\nU.S. Food and Drug Administration\n__________________________\n1 As of December 10, 2025, CDC broadened the definition for the outbreak investigation to include any infant with botulism who was exposed to ByHeart infant formula at any time since the product’s release in March 2022.","walmart-inc-720400-12122025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwalmart-inc-720400-12122025","2026-10-26T08:10:30.210283+00:00","2025-12-15","720400","Food & Beverages","Doug McMillon","2026-08-19T16:09:58.71+00:00","VIA Electronic Mail","2025-12-12",{"id":54,"raw":55,"subject":59,"body_html":60,"body_text":61,"firm_name":17,"letter_id":62,"created_at":63,"fei_number":20,"letter_url":64,"updated_at":65,"action_type":23,"case_status":24,"posted_date":66,"marcs_cms_no":67,"product_type":68,"closeout_date":20,"issuing_office":11,"recipient_name":49,"body_fetched_at":69,"delivery_method":70,"recipient_title":20,"reference_number":20,"action_taken_date":71,"medical_device_id":20,"response_letter_date":20},1336,[56,57,58,11,59,13,13,13],"\u003Ctime datetime=\"2024-07-30T13:20:00Z\">07\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-25T04:00:00Z\">07\u002F25\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwalmart-inc-683095-07252024\">Walmart, Inc.\u003C\u002Fa>","Finished Pharmaceuticals\u002FUnapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Doug McMillon\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Walmart, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>702 SW 8th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bentonville\u003C\u002Fspan>, \u003Cspan>AR\u003C\u002Fspan> \u003Cspan>72716-6299\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:HWSCSAFETY@wal-mart.com\"> HWSCSAFETY@wal-mart.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 25, 2024\u003C\u002Fp>\n\n\u003Cp>RE: 683095\u003C\u002Fp>\n\n\u003Cp>Dear Mr. McMillon:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of a chemical peel drug product that violates the Federal Food, Drug, and Cosmetic Act (the “FD&amp;C Act”). The United States Food and Drug Administration (FDA) reviewed “Skin Beauty Solutions lactic acid skin peel 90%,” a chemical peel drug product purchased on your website, www.walmart.com. As discussed further below, your firm is responsible for introducing or delivering for introduction into interstate commerce this product, which is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (the “FD&amp;C Act”), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce is prohibited under sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>FDA purchased “Skin Beauty Solutions lactic acid skin peel 90%” through your website, www.walmart.com. The product, which is a drug as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), was introduced or delivered for introduction into interstate commerce by Walmart via your Walmart Fulfillment Services.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>The Agency is concerned about potent chemical peel products that are available to be purchased and used by consumers. Such products pose a public health risk because they can cause skin injuries such as burns on the area of application, wounds, pain, swelling, and scarring. FDA has received adverse event reports of injuries involving use of such products, some of which required emergency room care, specialty care from a dermatologist, and\u002For surgical intervention.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“Skin Beauty Solutions lactic acid skin peel 90%” is a drug as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body. Examples of claims observed on the labeling of “Skin Beauty Solutions lactic acid skin peel 90%” that establish the intended use of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>From the product label:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“lactic acid skin peel”\u003C\u002Fli>\n\t\u003Cli>“Clears Acne &amp; Scars”\u003C\u002Fli>\n\t\u003Cli>“Removes Dead Skin Cells”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>“Skin Beauty Solutions lactic acid skin peel 90%” is not generally recognized as safe and effective for its above referenced uses and, therefore, is a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). There is no FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, in effect for “Skin Beauty Solutions lactic acid skin peel 90%.” Accordingly, the introduction or delivery of this product into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of past or present violations that may exist in connection with the products you distribute. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and\u002For injunction. Please submit a written response to this letter within fifteen working days from the date of receipt, explaining the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, including steps you will take to ensure that Walmart will no longer introduce or deliver for introduction into interstate commerce of, unapproved chemical peel drug products, as well as copies of related documentation. If you believe that the product you distribute is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration within fifteen working days from the date of receipt of this letter.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTina Smith, M.S\u003Cbr>\nCaptain, U.S Public Health Service\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Walmart distributes the product directly to individual U.S. consumers on behalf of third parties. The product was “fulfilled” by Walmart; your website states, “\u003Cem>Walmart Fulfillment Services (WFS) allows sellers to store their inventory at Walmart fulfillment centers. When a customer places an order on Walmart.com, we’ll pick, pack, and ship the item to the customer on your behalf. WFS also handles all customer support and returns for these orders\u003C\u002Fem>.” (See https:\u002F\u002Fsellerhelp.walmart.com\u002Fseller\u002Fs\u002Fguide?language=en_US&amp;article=000009214).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDoug McMillon\n\nRecipient Title\n\nPresident and CEO\n\nWalmart, Inc.\n\n702 SW 8th Street\n\nBentonville, AR 72716-6299\n\nUnited States\n\nHWSCSAFETY@wal-mart.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\n\nJuly 25, 2024\n\nRE: 683095\n\nDear Mr. McMillon:\n\nThis letter concerns your firm’s distribution of a chemical peel drug product that violates the Federal Food, Drug, and Cosmetic Act (the “FD&C Act”). The United States Food and Drug Administration (FDA) reviewed “Skin Beauty Solutions lactic acid skin peel 90%,” a chemical peel drug product purchased on your website, www.walmart.com. As discussed further below, your firm is responsible for introducing or delivering for introduction into interstate commerce this product, which is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (the “FD&C Act”), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce is prohibited under sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nFDA purchased “Skin Beauty Solutions lactic acid skin peel 90%” through your website, www.walmart.com. The product, which is a drug as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), was introduced or delivered for introduction into interstate commerce by Walmart via your Walmart Fulfillment Services.1\n\nThe Agency is concerned about potent chemical peel products that are available to be purchased and used by consumers. Such products pose a public health risk because they can cause skin injuries such as burns on the area of application, wounds, pain, swelling, and scarring. FDA has received adverse event reports of injuries involving use of such products, some of which required emergency room care, specialty care from a dermatologist, and\u002For surgical intervention.\n\nUnapproved New Drug\n\n“Skin Beauty Solutions lactic acid skin peel 90%” is a drug as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body. Examples of claims observed on the labeling of “Skin Beauty Solutions lactic acid skin peel 90%” that establish the intended use of this product as a drug include, but may not be limited to, the following:\n\nFrom the product label:\n\n“lactic acid skin peel”\n\n“Clears Acne & Scars”\n\n“Removes Dead Skin Cells”\n\n“Skin Beauty Solutions lactic acid skin peel 90%” is not generally recognized as safe and effective for its above referenced uses and, therefore, is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). There is no FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, in effect for “Skin Beauty Solutions lactic acid skin peel 90%.” Accordingly, the introduction or delivery of this product into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of past or present violations that may exist in connection with the products you distribute. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and\u002For injunction. Please submit a written response to this letter within fifteen working days from the date of receipt, explaining the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, including steps you will take to ensure that Walmart will no longer introduce or deliver for introduction into interstate commerce of, unapproved chemical peel drug products, as well as copies of related documentation. If you believe that the product you distribute is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration within fifteen working days from the date of receipt of this letter.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTina Smith, M.S\n\nCaptain, U.S Public Health Service\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n________________________\n\n1 Walmart distributes the product directly to individual U.S. consumers on behalf of third parties. The product was “fulfilled” by Walmart; your website states, “Walmart Fulfillment Services (WFS) allows sellers to store their inventory at Walmart fulfillment centers. When a customer places an order on Walmart.com, we’ll pick, pack, and ship the item to the customer on your behalf. WFS also handles all customer support and returns for these orders.” (See https:\u002F\u002Fsellerhelp.walmart.com\u002Fseller\u002Fs\u002Fguide?language=en_US&article=000009214).","walmart-inc-683095-07252024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwalmart-inc-683095-07252024","2026-10-26T08:10:30.147024+00:00","2024-07-30","683095","Drugs","2026-08-19T23:55:51.638+00:00","Via Email","2024-07-25",{"id":73,"raw":74,"subject":79,"body_html":80,"body_text":81,"firm_name":82,"letter_id":83,"created_at":84,"fei_number":20,"letter_url":85,"updated_at":86,"action_type":23,"case_status":24,"posted_date":87,"marcs_cms_no":88,"product_type":68,"closeout_date":20,"issuing_office":78,"recipient_name":49,"body_fetched_at":89,"delivery_method":70,"recipient_title":20,"reference_number":20,"action_taken_date":90,"medical_device_id":20,"response_letter_date":20},1926,[75,76,77,78,79,13,13,13],"\u003Ctime datetime=\"2023-08-22T13:20:00Z\">08\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-18T04:00:00Z\">08\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwalmart-inc-648620-08182023\">Walmart, Inc\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Doug McMillon\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Walmart, Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>702 SW 8th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bentonville\u003C\u002Fspan>, \u003Cspan>AR\u003C\u002Fspan> \u003Cspan>72716-6299\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:HWSCSAFETY@wal-mart.com\"> HWSCSAFETY@wal-mart.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 18, 2023\u003C\u002Fp>\n\n\u003Cp>RE: 648620\u003C\u002Fp>\n\n\u003Cp>Dear Mr. McMillon:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of the “Naturasil Molluscum Treatment Kit,” a product intended to treat molluscum contagiosum, sold on your website www.walmart.com. As discussed below, your firm is responsible for introducing or delivering for introduction into interstate commerce of this product, which is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (the “FD&amp;C Act”), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce is prohibited under sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) purchased “Naturasil Molluscum Treatment Kit”\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> through your website, www.walmart.com. The product, which is a drug as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), was introduced or delivered for introduction into interstate commerce by Walmart via your Walmart Fulfillment Services.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Molluscum contagiosum is not a condition amenable to self-diagnosis and treatment, and there are no legally marketed over-the-counter (OTC) drug products to treat this condition. Molluscum contagiosum is a viral skin infection characterized by small, raised lesions on the skin that are known as Mollusca. Molluscum affects both children and adults; however, it is more common in children. In healthy individuals, the lesions usually disappear spontaneously within 6 to 12 months, although in some cases, it could take years to resolve. In sexually active individuals, the lesions found in the genital region are considered a sexually transmitted disease\u002Finfection (STD\u002FSTI). In addition, patients with new or existing skin lesions should seek out a healthcare professional to be evaluated. A healthcare professional is needed to rule out the possibility of a more serious condition, such as, skin cancer, fungal infection, and for the genitalia, anogenital warts. The “Naturasil Molluscum Treatment Kit” product is especially concerning from a public health perspective because it is marketed for use in children. In addition, FDA is concerned that people are forgoing or delaying proper diagnosis and treatment of a potentially serious, undiagnosed health condition by purchasing and using an unapproved drug product claiming to treat molluscum contagiosum.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“Naturasil Molluscum Treatment Kit” is a drug as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the labeling of “Naturasil Molluscum Treatment Kit”\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> that establish the intended use of this product as a drug include, but may not be limited to, the following:\u003Cbr>\n• In the name of the product – “Molluscum Treatment Kit”\u003Cbr>\n• On the Drug Facts label under “Uses” – “Symptomatic treatment of molluscum contagiosum.”\u003Cbr>\n• “Now you can eradicate Molluscum Contagiosum at home with our Two-Part Molluscum Treatment Kit.”\u003Cbr>\n• “Naturasil Molluscum Treatment Kit is recommended as a fast, natural solution that eliminates the need for an expensive dermatologist’s visit.”\u003C\u002Fp>\n\n\u003Cp>“Naturasil Molluscum Treatment Kit” is not generally recognized as safe and effective for the above referenced uses and, therefore, is a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). There is no FDA-approved application in effect for “Naturasil Molluscum Treatment Kit.”\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of past or present violations that may exist in connection with the products you distribute. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and\u002For injunction. Please submit a written response to this letter within fifteen working days from the date of receipt, explaining the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, including steps you will take to ensure that Walmart will no longer introduce, deliver, or cause the introduction or delivery into interstate commerce of, unapproved new drugs products claiming to treat molluscum contagiosum, as well as copies of related documentation. If you believe that the product you distribute is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration within fifteen working days from the date of receipt of this letter.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Furman\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The kit is composed of “Naturasil Molluscum Relief Soap” and “Naturasil Molluscum Topical Liquid.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Walmart distributes the product directly to individual U.S. consumers on behalf of third parties. The product was “fulfilled” by \u003Cem>Walmart; your website states, “Walmart Fulfillment Services (WFS) allows sellers to store their inventory at Walmart fulfillment centers. When a customer places an order on Walmart.com, we’ll pick, pack, and ship the item(s) to the customer on your behalf. WFS also handles all customer support and returns for these orders\u003C\u002Fem>.” (See https:\u002F\u002Fsellerhelp.walmart.com\u002Fseller\u002Fs\u002Fguide?language=en_US&amp;article=000009214).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> This product is marketed as being “child-safe (2 yrs &amp; above).”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> We recognize that the “Naturasil Molluscum Treatment Kit” labeling describes the product as being “homeopathic.”\u003C\u002Fp>\n\n\u003Cp>First, we note that under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States without the required FDA approval. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” “Naturasil Molluscum Treatment Kit” includes non-homeopathic ingredients that, although listed as “inactive ingredients,” are considered active ingredients under 21 C.F.R. 201.66(b)(2) because they are promoted with claims to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or any function of the body. These other active ingredients are not listed in dilutions and at least some are not listed in the HPUS, and thus these products fall outside the scope of products addressed in this guidance. Notwithstanding, even if “Naturasil Molluscum Treatment Kit” was considered a “homeopathic drug product\" under this guidance, this product would fall under the guidance’s categories of homeopathic drug products marketed without the required FDA approval that FDA views as potentially posing higher risks to public health, and thus intends to prioritize for enforcement and regulatory actions.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDoug McMillon\n\nRecipient Title\n\nPresident and CEO\n\nWalmart, Inc\n\n702 SW 8th Street\n\nBentonville, AR 72716-6299\n\nUnited States\n\nHWSCSAFETY@wal-mart.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nAugust 18, 2023\n\nRE: 648620\n\nDear Mr. McMillon:\n\nThis letter concerns your firm’s distribution of the “Naturasil Molluscum Treatment Kit,” a product intended to treat molluscum contagiosum, sold on your website www.walmart.com. As discussed below, your firm is responsible for introducing or delivering for introduction into interstate commerce of this product, which is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (the “FD&C Act”), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce is prohibited under sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nThe United States Food and Drug Administration (FDA) purchased “Naturasil Molluscum Treatment Kit”1 through your website, www.walmart.com. The product, which is a drug as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), was introduced or delivered for introduction into interstate commerce by Walmart via your Walmart Fulfillment Services.2\n\nMolluscum contagiosum is not a condition amenable to self-diagnosis and treatment, and there are no legally marketed over-the-counter (OTC) drug products to treat this condition. Molluscum contagiosum is a viral skin infection characterized by small, raised lesions on the skin that are known as Mollusca. Molluscum affects both children and adults; however, it is more common in children. In healthy individuals, the lesions usually disappear spontaneously within 6 to 12 months, although in some cases, it could take years to resolve. In sexually active individuals, the lesions found in the genital region are considered a sexually transmitted disease\u002Finfection (STD\u002FSTI). In addition, patients with new or existing skin lesions should seek out a healthcare professional to be evaluated. A healthcare professional is needed to rule out the possibility of a more serious condition, such as, skin cancer, fungal infection, and for the genitalia, anogenital warts. The “Naturasil Molluscum Treatment Kit” product is especially concerning from a public health perspective because it is marketed for use in children. In addition, FDA is concerned that people are forgoing or delaying proper diagnosis and treatment of a potentially serious, undiagnosed health condition by purchasing and using an unapproved drug product claiming to treat molluscum contagiosum.\n\nUnapproved New Drug\n\n“Naturasil Molluscum Treatment Kit” is a drug as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims observed on the labeling of “Naturasil Molluscum Treatment Kit”3 that establish the intended use of this product as a drug include, but may not be limited to, the following:\n\n• In the name of the product – “Molluscum Treatment Kit”\n\n• On the Drug Facts label under “Uses” – “Symptomatic treatment of molluscum contagiosum.”\n\n• “Now you can eradicate Molluscum Contagiosum at home with our Two-Part Molluscum Treatment Kit.”\n\n• “Naturasil Molluscum Treatment Kit is recommended as a fast, natural solution that eliminates the need for an expensive dermatologist’s visit.”\n\n“Naturasil Molluscum Treatment Kit” is not generally recognized as safe and effective for the above referenced uses and, therefore, is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). There is no FDA-approved application in effect for “Naturasil Molluscum Treatment Kit.”4 Accordingly, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of past or present violations that may exist in connection with the products you distribute. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and\u002For injunction. Please submit a written response to this letter within fifteen working days from the date of receipt, explaining the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, including steps you will take to ensure that Walmart will no longer introduce, deliver, or cause the introduction or delivery into interstate commerce of, unapproved new drugs products claiming to treat molluscum contagiosum, as well as copies of related documentation. If you believe that the product you distribute is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration within fifteen working days from the date of receipt of this letter.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Furman\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n________________________\n\n1 The kit is composed of “Naturasil Molluscum Relief Soap” and “Naturasil Molluscum Topical Liquid.”\n\n2 Walmart distributes the product directly to individual U.S. consumers on behalf of third parties. The product was “fulfilled” by Walmart; your website states, “Walmart Fulfillment Services (WFS) allows sellers to store their inventory at Walmart fulfillment centers. When a customer places an order on Walmart.com, we’ll pick, pack, and ship the item(s) to the customer on your behalf. WFS also handles all customer support and returns for these orders.” (See https:\u002F\u002Fsellerhelp.walmart.com\u002Fseller\u002Fs\u002Fguide?language=en_US&article=000009214).\n\n3 This product is marketed as being “child-safe (2 yrs & above).”\n\n4 We recognize that the “Naturasil Molluscum Treatment Kit” labeling describes the product as being “homeopathic.”\n\nFirst, we note that under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\n\nIn addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States without the required FDA approval. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” “Naturasil Molluscum Treatment Kit” includes non-homeopathic ingredients that, although listed as “inactive ingredients,” are considered active ingredients under 21 C.F.R. 201.66(b)(2) because they are promoted with claims to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or any function of the body. These other active ingredients are not listed in dilutions and at least some are not listed in the HPUS, and thus these products fall outside the scope of products addressed in this guidance. Notwithstanding, even if “Naturasil Molluscum Treatment Kit” was considered a “homeopathic drug product\" under this guidance, this product would fall under the guidance’s categories of homeopathic drug products marketed without the required FDA approval that FDA views as potentially posing higher risks to public health, and thus intends to prioritize for enforcement and regulatory actions.","Walmart, Inc","walmart-inc-648620-08182023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwalmart-inc-648620-08182023","2026-10-26T08:10:30.092404+00:00","2023-08-22","648620","2026-08-20T00:47:05.534+00:00","2023-08-18",{"id":92,"raw":93,"subject":97,"body_html":98,"body_text":99,"firm_name":100,"letter_id":101,"created_at":102,"fei_number":20,"letter_url":103,"updated_at":104,"action_type":23,"case_status":24,"posted_date":105,"marcs_cms_no":106,"product_type":68,"closeout_date":20,"issuing_office":78,"recipient_name":49,"body_fetched_at":107,"delivery_method":70,"recipient_title":20,"reference_number":20,"action_taken_date":108,"medical_device_id":20,"response_letter_date":20},2376,[94,95,96,78,97,13,13,13],"\u003Ctime datetime=\"2022-11-01T13:20:00Z\">11\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-10-28T04:00:00Z\">10\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwalmart-inc-631755-10282022\">Walmart Inc.\u003C\u002Fa>","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Doug McMillon\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Walmart Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>702 SW 8th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bentonville\u003C\u002Fspan>, \u003Cspan>AR\u003C\u002Fspan> \u003Cspan>72716-6299\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:HWSCSAFETY@wal-mart.com\"> HWSCSAFETY@wal-mart.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 28, 2022\u003C\u002Fp>\n\n\u003Cp>RE: 631755\u003C\u002Fp>\n\n\u003Cp>Dear Mr. McMillon:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of the “Artri King Reforzado con Ortiga y Omega 3” product that violates the Federal Food, Drug, and Cosmetic Act (the “FD&amp;C Act”). As discussed below, your firm is responsible for introducing, delivering, or causing the introduction or delivery into interstate commerce of this product, which is an unapproved new drug under section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Furthermore, this product is a misbranded drug under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a). As explained further below, introducing or delivering this product for introduction into interstate commerce is prohibited under sections 301(a), 301(d), and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(a), 331(d), and 355(a). You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>FDA purchased “Artri King Reforzado con Ortiga y Omega 3” through your website, www.walmart.com. The product, which is a drug as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), was introduced or delivered for introduction into interstate commerce by Walmart via your Walmart Fulfillment Services.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> FDA confirmed through laboratory analyses that the “Artri King Reforzado con Ortiga y Omega 3” purchased on Walmart.com contained the active pharmaceutical ingredient (API) diclofenac, which is not listed on the product label.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Diclofenac is a non-steroidal anti-inflammatory drug (NSAID).\u003Csup>\u003Cem>\u003Cstrong>3, 4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> NSAIDs may cause increased risk of cardiovascular events, such as heart attack and stroke, as well as serious gastrointestinal damage, including bleeding, ulceration, and fatal perforation of the stomach and intestines. The undeclared diclofenac ingredient in “Artri King Reforzado con Ortiga y Omega 3” may also interact with other medications and significantly increase the risk of adverse events, particularly when consumers use multiple NSAID-containing products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“Artri King Reforzado con Ortiga y Omega 3” is a drug as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the labeling of “Artri King Reforzado con Ortiga y Omega 3” that establish the intended use of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“PROPRIEDADES” (English translation: \u003Cem>PROPERTIES\u003C\u002Fem>)\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Altamente eficaz en la reconstruccion del cartílago.” (English translation: \u003Cem>Highly effective in restoring cartilage\u003C\u002Fem>.)\u003C\u002Fli>\n\t\u003Cli>“Combate la artritis.” (English translation: \u003Cem>Fights arthritis\u003C\u002Fem>.)\u003C\u002Fli>\n\t\u003Cli>“Detiene el avance de deterioro en articulaciones.” (English translation: \u003Cem>Stops the progress of joint deterioration\u003C\u002Fem>.)\u003C\u002Fli>\n\t\u003Cli>“Antiinflamatorio y analgésico.” (English translation: \u003Cem>Anti-inflammatory and analgesic\u003C\u002Fem>.)\u003C\u002Fli>\n\t\u003Cli>“Eficaz en problemas de articulaciones de lesiones deportivas.” (English translation: \u003Cem>Effective for joint problems due to sports injuries\u003C\u002Fem>.)\u003C\u002Fli>\n\t\u003Cli>“Beneficia a personas que padecen de procesos degenerativos como artritis y osteoartritis.” (English translation: \u003Cem>Benefits people suffering from degenerative processes such as arthritis and osteoarthritis\u003C\u002Fem>.)\u003C\u002Fli>\n\t\u003Cli>“Mejora la movilidad y normal funcionamiento de las articulaciones.” (English translation: \u003Cem>Improves mobility and normal functioning of joints\u003C\u002Fem>.)\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>“Artri King Reforzado con Ortiga y Omega 3” is not generally recognized as safe and effective for the above referenced uses and therefore is a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). There are no FDA-approved applications in effect for “Artri King Reforzado con Ortiga y Omega 3.” Introduction or delivery of this product into interstate commerce without an approved application violates sections 301(d), 21 U.S.C. 331(d), and 505(a), 21 U.S.C. 355(a) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>In addition, “Artri King Reforzado con Ortiga y Omega 3” is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a). Under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), a drug is misbranded if its labeling is false or misleading in any particular. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that, in determining whether an article's labeling or advertising “is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in light of such representations.” The labeling for “Artri King Reforzado con Ortiga y Omega 3” does not declare that the products contain the drug ingredient diclofenac. As discussed earlier, diclofenac can lead to adverse cardiovascular events, such as heart attack and stroke, or serious gastrointestinal damage, including bleeding, ulceration, and fatal tears of the stomach and intestines, or liver toxicity including liver failure that can cause the need for a liver transplant or death. The failure to disclose this ingredient in the product’s labeling renders “Artri King Reforzado con Ortiga y Omega 3” misbranded under section 502(a) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>The introduction, delivery for introduction, or causing the introduction or delivery for introduction into interstate commerce of this misbranded drug is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of past or present violations that may exist in connection with the products you distribute. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and\u002For injunction. Please submit a written response to this letter within fifteen working days from the date of receipt, explaining the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that the product you distribute is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration within fifteen working days from the date of receipt of this letter.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nCarolyn Becker\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Walmart distributes the product directly to individual U.S. consumers on behalf of third parties. The product discussed below was “fulfilled” by Walmart; your website states, “\u003Cem>Walmart Fulfillment Services (WFS) offers end-toend fulfillment services for third-party ecommerce sellers. With one of the world’s largest supply chains, we’re uniquely positioned to provide the scale, quality, cost, and efficiency you need to grow a successful business on Walmart.com. . . . 4. We store, pick, pack, and ship your orders 5. We handle customer care and returns (in store or home pickup\u003C\u002Fem>).” (see https:\u002F\u002Fmarketplace.walmart.com\u002Fwalmart-fulfillment-services\u002F).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> U.S. Food &amp; Drug Administration, \u003Cem>Public Notification: Artri Ajo King contains hidden drug ingredient\u003C\u002Fem>, (January 5, 2022), \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-artri-ajo-king-contains-hidden-drug-ingredient\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-artri-ajo-king-contains-hidden-drug-ingredient\u003C\u002Fa>; U.S. Food &amp; Drug Administration (@FDA_Drug_Info), Twitter (March 4, 2022, 3:07PM) https:\u002F\u002Ftwitter.com\u002FFDA_Drug_Info\u002Fstatus\u002F1499838990631026689; U.S. Food &amp; Drug Administration,\u003Cem> Consumer Alert: Artri Ajo King\u003C\u002Fem>, Facebook (March 4, 2022), https:\u002F\u002Fwww.facebook.com\u002FFDA\u002Fposts\u002F328441589313206; U.S. Food &amp; Drug Administration, \u003Cem>Public Notification: Artri King contains hidden drug ingredient\u003C\u002Fem>, (April 20, 2022),&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-artri-king-contains-hidden-drug-ingredients\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-artri-king-contains-hidden-drug-ingredients\u003C\u002Fa>; U.S. Food &amp; Drug Administration, \u003Cem>Public Notification: Ortiga Mas Ajo Rey contains hidden drug ingredient\u003C\u002Fem>, (April 20, 2022), \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-ortiga-mas-ajo-rey-contains-hidden-drug-ingredient\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-ortiga-mas-ajo-rey-contains-hidden-drug-ingredient\u003C\u002Fa>; U.S. Food &amp; Drug Administration, \u003Cem>Public Notification: Ortiga Mas Ajo Rey - Extra Forte contains hidden drug ingredient\u003C\u002Fem>, (April 20, 2022), \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-ortiga-mas-ajorey-extra-forte-contains-hidden-drug-ingredients\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-ortiga-mas-ajorey-extra-forte-contains-hidden-drug-ingredients\u003C\u002Fa>; U.S. Food &amp; Drug Administration, \u003Cem>FDA warns consumers not to purchase or use Artri and Ortiga products, which may contain hidden drug ingredients\u003C\u002Fem>, (April 20, 2022),&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-warns-consumers-not-purchase-or-use-artri-and-ortiga-products-which-may-contain-hidden-drug\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-warns-consumers-not-purchase-or-use-artri-and-ortiga-products-which-may-contain-hidden-drug\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Please be advised that under section 201(ff)(3)(B)(i) of the FD&amp;C Act, 21 U.S.C. § 321(ff)(3)(B)(i), a dietary supplement may not include an article that is approved as a new drug under section 505 of the FD&amp;C Act, unless that article was marketed as a dietary supplement or food before its approval as a drug. FDA approved Voltaren (containing diclofenac sodium as the active ingredient) as a new drug on July 28, 1988. Prior to that date, diclofenac had not been marketed as a food or dietary supplement. Given that diclofenac was not marketed as a dietary supplement or as a food before Voltaren was approved, a product marketed as a dietary supplement that contains diclofenac is excluded from the definition of a dietary supplement under section 201(ff)(3)(B)(i) of the FD&amp;C Act. Furthermore, a product marketed as a dietary supplement that is intended for the treatment of arthritis is also a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> We also note that the labeling of the product appears to violate Walmart’s policies prohibiting dietary supplements with disease claims from being listed on Walmart Marketplace: https:\u002F\u002Fgecrm.my.salesforce.com\u002Fsfc\u002Fp\u002F61000000ZKTc\u002Fa\u002F4M000000LnEm\u002FYFluE07nRPxGwEBEosayC29sEDWdKBGNLikZxfiLL8c.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDoug McMillon\n\nRecipient Title\n\nCEO\n\nWalmart Inc.\n\n702 SW 8th Street\n\nBentonville, AR 72716-6299\n\nUnited States\n\nHWSCSAFETY@wal-mart.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nOctober 28, 2022\n\nRE: 631755\n\nDear Mr. McMillon:\n\nThis letter concerns your firm’s distribution of the “Artri King Reforzado con Ortiga y Omega 3” product that violates the Federal Food, Drug, and Cosmetic Act (the “FD&C Act”). As discussed below, your firm is responsible for introducing, delivering, or causing the introduction or delivery into interstate commerce of this product, which is an unapproved new drug under section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Furthermore, this product is a misbranded drug under section 502(a) of the FD&C Act, 21 U.S.C. 352(a). As explained further below, introducing or delivering this product for introduction into interstate commerce is prohibited under sections 301(a), 301(d), and 505(a) of the FD&C Act, 21 U.S.C. 331(a), 331(d), and 355(a). You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nFDA purchased “Artri King Reforzado con Ortiga y Omega 3” through your website, www.walmart.com. The product, which is a drug as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), was introduced or delivered for introduction into interstate commerce by Walmart via your Walmart Fulfillment Services.1 FDA confirmed through laboratory analyses that the “Artri King Reforzado con Ortiga y Omega 3” purchased on Walmart.com contained the active pharmaceutical ingredient (API) diclofenac, which is not listed on the product label.2 Diclofenac is a non-steroidal anti-inflammatory drug (NSAID).3, 4 NSAIDs may cause increased risk of cardiovascular events, such as heart attack and stroke, as well as serious gastrointestinal damage, including bleeding, ulceration, and fatal perforation of the stomach and intestines. The undeclared diclofenac ingredient in “Artri King Reforzado con Ortiga y Omega 3” may also interact with other medications and significantly increase the risk of adverse events, particularly when consumers use multiple NSAID-containing products.\n\nUnapproved New Drugs\n\n“Artri King Reforzado con Ortiga y Omega 3” is a drug as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims observed on the labeling of “Artri King Reforzado con Ortiga y Omega 3” that establish the intended use of this product as a drug include, but may not be limited to, the following:\n\n“PROPRIEDADES” (English translation: PROPERTIES)\n\n“Altamente eficaz en la reconstruccion del cartílago.” (English translation: Highly effective in restoring cartilage.)\n\n“Combate la artritis.” (English translation: Fights arthritis.)\n\n“Detiene el avance de deterioro en articulaciones.” (English translation: Stops the progress of joint deterioration.)\n\n“Antiinflamatorio y analgésico.” (English translation: Anti-inflammatory and analgesic.)\n\n“Eficaz en problemas de articulaciones de lesiones deportivas.” (English translation: Effective for joint problems due to sports injuries.)\n\n“Beneficia a personas que padecen de procesos degenerativos como artritis y osteoartritis.” (English translation: Benefits people suffering from degenerative processes such as arthritis and osteoarthritis.)\n\n“Mejora la movilidad y normal funcionamiento de las articulaciones.” (English translation: Improves mobility and normal functioning of joints.)\n\n“Artri King Reforzado con Ortiga y Omega 3” is not generally recognized as safe and effective for the above referenced uses and therefore is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). There are no FDA-approved applications in effect for “Artri King Reforzado con Ortiga y Omega 3.” Introduction or delivery of this product into interstate commerce without an approved application violates sections 301(d), 21 U.S.C. 331(d), and 505(a), 21 U.S.C. 355(a) of the FD&C Act.\n\nIn addition, “Artri King Reforzado con Ortiga y Omega 3” is misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a). Under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), a drug is misbranded if its labeling is false or misleading in any particular. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that, in determining whether an article's labeling or advertising “is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in light of such representations.” The labeling for “Artri King Reforzado con Ortiga y Omega 3” does not declare that the products contain the drug ingredient diclofenac. As discussed earlier, diclofenac can lead to adverse cardiovascular events, such as heart attack and stroke, or serious gastrointestinal damage, including bleeding, ulceration, and fatal tears of the stomach and intestines, or liver toxicity including liver failure that can cause the need for a liver transplant or death. The failure to disclose this ingredient in the product’s labeling renders “Artri King Reforzado con Ortiga y Omega 3” misbranded under section 502(a) of the FD&C Act.\n\nThe introduction, delivery for introduction, or causing the introduction or delivery for introduction into interstate commerce of this misbranded drug is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of past or present violations that may exist in connection with the products you distribute. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and\u002For injunction. Please submit a written response to this letter within fifteen working days from the date of receipt, explaining the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that the product you distribute is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration within fifteen working days from the date of receipt of this letter.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn Becker\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n__________________________\n\n1 Walmart distributes the product directly to individual U.S. consumers on behalf of third parties. The product discussed below was “fulfilled” by Walmart; your website states, “Walmart Fulfillment Services (WFS) offers end-toend fulfillment services for third-party ecommerce sellers. With one of the world’s largest supply chains, we’re uniquely positioned to provide the scale, quality, cost, and efficiency you need to grow a successful business on Walmart.com. . . . 4. We store, pick, pack, and ship your orders 5. We handle customer care and returns (in store or home pickup).” (see https:\u002F\u002Fmarketplace.walmart.com\u002Fwalmart-fulfillment-services\u002F).\n\n2 U.S. Food & Drug Administration, Public Notification: Artri Ajo King contains hidden drug ingredient, (January 5, 2022), https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-artri-ajo-king-contains-hidden-drug-ingredient; U.S. Food & Drug Administration (@FDA_Drug_Info), Twitter (March 4, 2022, 3:07PM) https:\u002F\u002Ftwitter.com\u002FFDA_Drug_Info\u002Fstatus\u002F1499838990631026689; U.S. Food & Drug Administration, Consumer Alert: Artri Ajo King, Facebook (March 4, 2022), https:\u002F\u002Fwww.facebook.com\u002FFDA\u002Fposts\u002F328441589313206; U.S. Food & Drug Administration, Public Notification: Artri King contains hidden drug ingredient, (April 20, 2022), https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-artri-king-contains-hidden-drug-ingredients; U.S. Food & Drug Administration, Public Notification: Ortiga Mas Ajo Rey contains hidden drug ingredient, (April 20, 2022), https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-ortiga-mas-ajo-rey-contains-hidden-drug-ingredient; U.S. Food & Drug Administration, Public Notification: Ortiga Mas Ajo Rey - Extra Forte contains hidden drug ingredient, (April 20, 2022), https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fpublic-notification-ortiga-mas-ajorey-extra-forte-contains-hidden-drug-ingredients; U.S. Food & Drug Administration, FDA warns consumers not to purchase or use Artri and Ortiga products, which may contain hidden drug ingredients, (April 20, 2022), https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-warns-consumers-not-purchase-or-use-artri-and-ortiga-products-which-may-contain-hidden-drug.\n\n3 Please be advised that under section 201(ff)(3)(B)(i) of the FD&C Act, 21 U.S.C. § 321(ff)(3)(B)(i), a dietary supplement may not include an article that is approved as a new drug under section 505 of the FD&C Act, unless that article was marketed as a dietary supplement or food before its approval as a drug. FDA approved Voltaren (containing diclofenac sodium as the active ingredient) as a new drug on July 28, 1988. Prior to that date, diclofenac had not been marketed as a food or dietary supplement. Given that diclofenac was not marketed as a dietary supplement or as a food before Voltaren was approved, a product marketed as a dietary supplement that contains diclofenac is excluded from the definition of a dietary supplement under section 201(ff)(3)(B)(i) of the FD&C Act. Furthermore, a product marketed as a dietary supplement that is intended for the treatment of arthritis is also a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease.\n\n4 We also note that the labeling of the product appears to violate Walmart’s policies prohibiting dietary supplements with disease claims from being listed on Walmart Marketplace: https:\u002F\u002Fgecrm.my.salesforce.com\u002Fsfc\u002Fp\u002F61000000ZKTc\u002Fa\u002F4M000000LnEm\u002FYFluE07nRPxGwEBEosayC29sEDWdKBGNLikZxfiLL8c.","Walmart Inc.","walmart-inc-631755-10282022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwalmart-inc-631755-10282022","2026-10-26T08:10:30.042653+00:00","2022-11-01","631755","2026-08-20T01:28:58.568+00:00","2022-10-28",5,{"510k":111,"classification":112,"enforcement":113,"event":114,"event_backfill":115,"pma":116,"warning_letter":117},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-20T04:00:32.497+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]